

A Simple and Efficient Synthesis of N-Substituted Cyclohex-3-enamines

Mónica Álvarez-Pérez,*¹ José Marco-Contelles*

Laboratorio de Radicales Libres y Química Computacional, IQOG (CSIC), C/ Juan de la Cierva 3, 28006 Madrid, Spain
Fax +34(91)3944103; E-mail: monicaap@quim.ucm.es; E-mail: iqoc21@iqog.csic.es

Received 26 April 2009; revised 22 June 2009

Abstract: A straightforward preparation of N-substituted cyclohex-3-enamines starting from the commercially available *trans*-4-aminocyclohexanol hydrochloride is described. Cyclohex-3-enamino-functionalized compounds have proven to be interesting intermediates in medicinal chemistry. The method here described is cheaper, more scalable and tolerant of a broader variety of functional groups than those found in the literature for this type of compound.

Key words: eliminations, olefinations, medicinal chemistry, amines, nitrogenated cyclohexenes


Cyclohexenes containing a nitrogen atom at the homoallylic position have proven to be useful intermediates for the synthesis of bicyclic heterocycles such as 7-azabicyclo[2.2.1]heptanes^{2,3} or 6-azabicyclo[3.2.1]octanes.⁴ Both are present in pharmacologically interesting alkaloids: the former in epibatidine,⁵ the latter in azapropfen⁶ and hetisine.⁷

Traditionally, cyclohexenes have been synthesized by Diels–Alder cycloadditions (DA), however, the DA approach requires the use of complex dienophiles⁸ or subsequent rearrangement reactions⁹ when a nitrogen atom at the 3-position is needed. Ring-closing-metathesis reactions (RCM) have been presented as an alternative to DA reactions for the synthesis of these interesting intermediates.¹⁰ Nevertheless, high cost and problems in scaling-up are significant drawbacks for the use of RCM as a synthetic route to simple cyclohex-3-enamine derivatives.

We previously described the synthesis of epibatidine analogues² and, particularly, 7-azabicyclo[2.2.1]heptanes¹¹ using commercially available cyclohex-3-enecarboxylic acid as starting material.³ However, because scaling up this sequence presented both technical difficulties and safety issues, it became necessary to develop a new protocol which reduced the cost of these useful compounds, was scalable without loss of efficiency and, very importantly, allowed the preparation of a broad variety of cyclohex-3-enamine derivatives starting from the same compound. We wondered if *trans*-4-aminocyclohexanol hydrochloride (**1a**·HCl) would be a suitable starting compound for our purposes.¹²

A large number of catalysts and reagents have been developed for olefin syntheses via alcohols.¹³ Nevertheless, the

presence of a nitrogenated moiety in a molecule can be expected to cause a decrease in selectivity as it may react with the reagent⁴ and/or participate in a cyclodehydration process.^{12,14} Bearing this in mind, a preliminary evaluation of conditions for the dehydration of compounds **1a–c** was carried out (Scheme 1, Table 1). Our first attempt, using phosphorus oxychloride (POCl₃) in pyridine to dehydrate **1a**·HCl (entry 1, Table 1)¹⁵ gave a complex mixture, the analysis of which proved to be difficult. A similar result was observed when the same conditions were applied to *trans*-4-benzylaminocyclohexanol (**1b**; entry 2). It is interesting to note that when triethylamine was used instead of pyridine in the case of amine **1b**,¹⁵ a 54% yield of the corresponding cyclodehydration product **4b**^{12b} could be isolated (entry 3).



Scheme 1

We then decided to use the Boc protecting group and prepared *tert*-butyl-*trans*-4-hydroxycyclohexylcarbamate (**1c**).¹⁶ When testing the POCl₃ in pyridine system in this case, the desired functionalized cyclohexene **2c**³ was obtained, although in a moderate yield of 52% (entry 4). Thus, different dehydration conditions were investigated. Thionyl chloride (SOCl₂) was chosen and used first on compound **1b**.¹⁵ In this case, the required functionalized cyclohexene **2b**⁴ was isolated in 27% yield, together with 20% yield of *N*-benzyl-*cis*-4-chlorocyclohexylamine (**3b**; entry 5). When applying the same reagent to compound **1c**, triethylamine had to be used in order to avoid deprotection of the Boc-carbamate.¹⁵ Unfortunately, significant decomposition was observed (entry 6). An additional attempt to prepare compound **2c** using SOCl₂ was performed as showed in entry 7; thus, *trans*-4-aminocyclohexanol (**1a**)¹⁷ was treated with SOCl₂ in chloroform as previously for **1b** and, before work-up, Boc₂O and potassium carbonate were added to the mixture.¹⁵ However, under these conditions, just 13% of **2c** could be isolated. The triphenylphosphine, iodine, and imidazole system¹⁸ was then employed as an alternative. These conditions should


Table 1 Preliminary Evaluation of Conditions for Dehydration of *trans*-4-Amino-Functionalized Cyclohexanols

Entry	Starting material	Conditions	Product	Yield (%) ^a
1	1a -HCl	POCl ₃ , py	mixture	–
2	1b	POCl ₃ , py	mixture	–
3	1b	POCl ₃ , Et ₃ N	4b ^{12b}	54
4	1c ¹⁶	POCl ₃ , py	2c ³	52
5	1b	SOCl ₂ , CHCl ₃ , reflux	2b ⁴ + 3b (X = Cl; 20%)	27
6	1c	SOCl ₂ , Et ₃ N	decomp.	–
7	1a ¹⁷	1) SOCl ₂ , CHCl ₃ 2) Boc ₂ O, K ₂ CO ₃	2c + 1c (10%)	13
8	1c	1) Ph ₃ P, I ₂ , imidazole 2) DBU, THF, reflux	2c	88

^a After isolation.

work in a similar way to the SOCl₂ reagent in the sense of promoting a halogenation process, but the iodinated intermediate should more readily generate the desired elimination product. Moreover, the drawbacks resulting from the acidic media that built up during the transformation would be avoided under these conditions. Bearing this in mind, **1c** was treated with triphenylphosphine, iodine, and imidazole in dichloromethane obtaining a 1:1.5 mixture of olefin **2c** and iodinated derivative **3c** (X = I). After heating this mixture with DBU at reflux in tetrahydrofuran, we were delighted to see that **2c** was the only product remaining and was isolated in 88% yield (entry 8).¹⁹ The sequence was then scaled up, with similar results.²⁰

In view of the results presented in Table 1, two main conclusions can be drawn: firstly, chemoselectivity is low when starting from amines, no matter which conditions are used (entries 1–3, 5 and 7); secondly, when starting from carbamates, only the combination of triphenylphosphine, iodine, and imidazole and DBU and tetrahydrofuran THF was efficient (entries 4, 6 and 8). Following this last result, the scope of the dehydration of *trans*-4-amino-functionalized cyclohexanols under these conditions was investigated (Scheme 2, Table 2). Carbamate **1d**⁴ provided not only the corresponding olefin **2d**⁴ (entry 1, Table 2) but also the amine **2b**,⁴ after removal of the Boc group (entry 2). Although deprotected amines did not give satisfactory results when used as starting materials, N-substituted cyclohex-3-enylamines can easily be obtained by using carbamate-protected starting materials and adding a deprotection step after dehydration. Amides also proved to be convenient functional groups for these reaction conditions (entries 3 and 4).^{21,22} Finally, sulfonamides were also shown to be tolerant to the described conditions and no cyclization product was observed (entry 5).¹²

**Scheme 2****Table 2** Reaction of *trans*-4-Amino-Functionalized Cyclohexanols with Triphenylphosphine, Iodine and Imidazole, and DBU

Entry	1	R ¹	R ²	Product	Ratio (2/3) ^a	Yield (%) ^b
1	1d ⁴	Bn	Boc	2d ⁴	1:8.6	63
2	1d	Bn	Boc	2b	1:8.6	55 ^c
3	1e ^{12b}	PhCO	H	2e	1.6:1	91
4	1f ²³	CF ₃ CO	H	2f ³	1:1.2	69
5	1g ^{12a}	Ts	H	2g ²⁴	1.3:1	87

^a Determined by ¹H NMR.^b Of isolated **2** after two steps from **1d**–**g**.^c After three steps from **1d**, including Boc-removal.

In summary, we herein present a method for the preparation of cyclohexenes bearing a nitrogenated functional group on the homoallylic position that formally consists of a dehydration process. Comparison to classical methods for dehydration in simple alcohols shows that the transformation does not occur satisfactorily under a broad variety of conditions. Starting materials and reagents needed are readily available and inexpensive and the procedure can easily be scaled up. Compared to other methodologies, the conditions described here allow the preparation of a broader variety of 3-nitrogenated cyclohexenes using the same starting material. The obtained products are potential intermediates in medicinal chemistry, which makes the methodology synthetically interesting and should make it the method of choice for the preparation of this type of compounds.

Unless otherwise stated, all reagents were purchased from commercial sources and used without further purification. Anhydrous solvents (CH₂Cl₂, THF) were obtained by passing the solvent through an activated alumina column on a PureSolvTM solvent purification system (Innovative Technologies, Inc., MA). Flash column chroma-

topography was carried out using silica gel C60 (230 mesh) as the stationary phase. Analytical thin layer chromatography was performed on 0.25 mm thick precoated silica gel plates (60F₂₅₄). Compounds were visualized under UV light at 254 nm or by staining with either a 1% ninhydrin in EtOH solution or with cerium molybdate. ¹H NMR and ¹³C NMR spectra were recorded at r.t. in CDCl₃, at 300, 400 or 500 MHz and at 75, 100 or 125 MHz, respectively, using solvent peaks [7.26 (H), 77.2 (C) ppm] as internal reference. The assignment of chemical shifts is based on standard NMR experiments (¹H, ¹³C-DEPT, ¹H, ¹H-COSY, gHSQC, gHMBC). Melting points were determined on a microscope type apparatus and are uncorrected. Mass spectra and elemental analysis were carried out by the mass spectrometry services at CQO (CSIC, Spain).

Preliminary Evaluation of Conditions (Table 1)

Entry 1: Compound **1a**-HCl (152 mg, 1 mmol) was treated with pyridine (1.65 mL, 20.4 mmol) under argon at r.t. then POCl₃ (0.27 mL, 2.9 mmol) was added dropwise (the solution became cloudy). After stirring overnight, the reaction was diluted in CH₂Cl₂ (10 mL) and aq CuSO₄ (1 M, 5 mL) was carefully added. The layers were separated and the organic layer was washed with H₂O (2 × 10 mL), dried over Na₂SO₄, filtrated and evaporated. The resulting crude product was analyzed by TLC and ¹H NMR.

Entry 3: A solution of *trans*-4-hydroxycyclohexylamine hydrochloride (**1a**-HCl; 2.50 g, 16.5 mmol) in MeOH (226 mL) was treated with NaOH (0.1 M in MeOH, 40 mL, 4 mmol, 0.24 equiv) under argon at r.t. Molecular sieves (4 Å) and PhCHO (1.67 mL, 16.5 mmol, 1 equiv) were added (the solution became cloudy), followed by a solution of NaBH₃CN (1.75 M in MeOH, 5.75 mL, 10.1 mmol, 0.61 equiv). 5 min after the end of the addition, a brown precipitate was observed. The reaction was stirred for 12 h, then the mixture was filtrated through Celite. The solid was washed with MeOH (3 × 100 mL) and the filtrate was treated with 1 M HCl until pH 1. Solvents were removed in vacuo and the resulting solid was redissolved in H₂O (200 mL) and extracted with Et₂O (3 × 100 mL). Layers were separated and the aqueous layer was basified with 1 N NaOH to basic pH, then extracted with CH₂Cl₂ (3 × 200 mL). The organic fractions were dried (MgSO₄) and the solvent removed in vacuo. The resulting crude product was purified by flash column chromatography (MeOH-CH₂Cl₂, 0.5% then 1 → 2 → 4 → 8 → 10%), giving *trans*-4-(benzylamino)cyclohexanol (**1b**).

1b

Yield: 2.70 g (80%); crystalline colorless solid; mp 87–89 °C.

IR (KBr): 3266, 3153, 3064, 3036, 2925, 2856, 2833, 1454, 1368, 1100, 1065, 918, 893, 748, 734, 697, 639 cm⁻¹.

¹H NMR (300 MHz, CDCl₃): δ = 7.41–7.12 (m, 5 H, ArH), 3.75 (s, 2 H, NCH₂), 3.55 (tt, *J* = 5.4, 3.3 Hz, 1 H, HCO), 2.45 (tt, *J* = 9.2, 2.8 Hz, 1 H, HCN), 2.00–1.81 (m, 4 H, 2 × CH₂), 1.80–1.58 (m, 2 H, NH, OH), 1.36–1.02 (m, 4 H, 2 × CH₂).

¹³C NMR (75 MHz, CDCl₃): δ = 140.5 (C), 128.6, 128.2, 127.1, 70.5, 55.5 (CH), 51.5, 34.0, 31.2 (CH₂).

MS (ES): *m/z* (%) = 206.2/207.2/208.2 [M + H]⁺.

Anal. Calcd for C₁₃H₁₉NO: C, 76.06; H, 9.33; N, 6.82. Found: C, 75.84; H, 9.30; N, 6.98.

Compound **1b** (108 mg, 0.53 mmol) in anhydrous CH₂Cl₂ (1.6 mL) was treated with Et₃N (0.08 mL, 0.54 mmol) under argon at r.t., then POCl₃ (0.05 mL, 0.54 mmol) was added dropwise (the mixture became slowly brown and warmed). After stirring overnight, the solvents were removed in vacuo and the crude product was purified by flash chromatography (MeOH-CH₂Cl₂, 2% + Et₃N 0.5%), to give several fractions in which only compound **4b**^{12b} (54 mg, 0.29 mmol, 54%) could be identified.

Entry 5: Compound **1b** (62 mg, 0.3 mmol) was dissolved in CHCl₃ (8.2 mL) and SOCl₂ (1.4 mL, 19.2 mmol) was slowly added at r.t. The mixture was heated at reflux overnight, then the solvents were removed in vacuo and toluene was added and evaporated several times. The resulting crude material was treated with sat. aq K₂CO₃ (10 mL) and CHCl₃ (20 mL), the layers were separated and the organic layer was washed with sat. aq K₂CO₃ (3 × 10 mL), dried over MgSO₄, filtrated and evaporated. The colorless oil was purified by flash chromatography (MeOH-CH₂Cl₂, 1% then 2 → 3 → 5%) to isolate the olefin **2b**⁴ as a colourless oil (15.2 mg, 0.081 mmol, 27%) and **3b**.

3b

Yield: 13.4 mg (20%); oil; *R*_f = 0.20 (MeOH-CH₂Cl₂, 5%).

IR (KBr): 3316, 2939, 2859, 1495, 1453, 1355, 1254, 1125, 736, 698 cm⁻¹.

¹H NMR (300 MHz, CDCl₃): δ = 7.36–7.22 (m, 5 H, ArH), 4.36–4.27 (m, 1 H, HCCl), 3.83 (s, 2 H, NCH₂), 2.60 (ddd, *J* = 12.5, 7.6, 5.2 Hz, 1 H, HCN), 2.10–1.98 (m, 2 H), 1.87–1.66 (m, 6 H), 1.48 (br s, 1 H, NH).

¹³C NMR (75 MHz, CDCl₃): δ = 140.9 (C), 128.7, 128.3, 127.1 (CH), 59.4, 54.4 (CH), 51.1, 32.8, 28.2 (CH₂).

HRMS-ESI: *m/z* [M + H]⁺ calcd for C₁₃H₁₉CIN: 224.1201; found: 224.1204.

Entry 6: Compound **1c**¹⁶ (65 mg, 0.3 mmol) was treated with Et₃N (8.2 mL) and SOCl₂ (0.6 mL, 8.23 mmol) was slowly added at r.t. After heating the mixture overnight at reflux, the excess of reagents was removed by distillation at normal pressure. The resulting black slurry was analysed by TLC and ¹H NMR: Decomposition was observed and no desired olefin was detected.

Entry 7: Compound **1a**¹⁷ (162 mg, 1.4 mmol) was treated in CHCl₃ (38 mL) with an excess of SOCl₂ (6.5 mL) and the resulting mixture was then heated at reflux overnight. After cooling, the solvent and the excess of reagent were removed in vacuo and toluene was added and evaporated several times. The residue was suspended in a 1:1 mixture of CHCl₃-Et₃N (14 mL) and cooled to 0 °C. K₂CO₃ (387 mg, 2.8 mmol) and Boc₂O (315 mg, 1.7 mmol) were then added and the reaction was stirred for 11 h while reaching r.t. After this time, the reaction was diluted with CHCl₃ (20 mL) and sat. aq K₂CO₃ (20 mL) was added. Layers were separated and the organic layer was washed with sat. aq K₂CO₃ (3 × 20 mL) and brine (20 mL), dried over MgSO₄, filtrated and evaporated. The resulting crude material was purified by flash chromatography (EtOAc-hexane, 2.5 → 6 → 20 → 50%). Seven different fractions were obtained, in which only **2c**³ (35.8 mg, 13%) and **1c**¹⁶ could be identified (30.7 mg, 10%).

Dehydration with Ph₃P, I₂, Imidazole, and DBU; General Procedure

The corresponding *trans*-4-hydroxycyclohexylamino-derivative **1**, imidazole (2.12 equiv) and Ph₃P (3.41 equiv) were dissolved in anhydrous CH₂Cl₂ (12 mL/mmol of **1**) under argon. A freshly prepared solution of I₂ (2.06 equiv) in anhydrous CH₂Cl₂ (12 mL/mmol of **1**) was slowly added at r.t. and the mixture kept stirring overnight. H₂O (20 mL/mmol of **1**) and further CH₂Cl₂ (20 mL/mmol of **1**) were then added and the layers separated. The organic layer was washed with sat. aq NaHCO₃ (3 × 20 mL/mmol of **1**), 5% aq Na₂SO₃ (3 × 20 mL/mmol of **1**) and sat. aq NaCl (2 × 20 mL/mmol of **1**) and dried (MgSO₄). After removing solvents in vacuo, the residue was purified by flash chromatography to obtain a mixture of compounds **2** and **3**, which was directly used in the next step. When compounds **2** and **3** showed different *R*_f values, a small fraction of the mixture was re-purified in order to characterize the intermediate **3**.

The mixture of **2** and **3** was diluted in THF (3.2 mL/mmol of **3**) and DBU (1 equiv) was added. The mixture was refluxed for 18 h, then the solvent was removed in vacuo. The residue was re-dissolved in Et₂O (50 mL/mmol of **3**), treated with 1 M HCl (25 mL/mmol of **3**) and the layers were separated. The aqueous layer was extracted with additional Et₂O (4 × 50 mL/mmol of **3**) and the organic fractions were dried (MgSO₄) and filtered. Solvents were removed in vacuo, giving **2** with satisfactory purity.

N-Benzylated Compounds

Following the general procedure for dehydration, compound **1b** (94 mg, 0.46 mmol) gave a complex mixture from which only *N*-benzyl-7-azabicyclo[2.2.1]heptane^{12b} (**4b**) could be identified (8 mg, 0.04 mmol, 9%).

tert-Butyl Benzyl(*trans*-4-hydroxycyclohexyl)carbamate (**1d**)⁴

A solution of **1b** (259 mg, 1.26 mmol) in CHCl₃ (2 mL) was cooled to 0 °C and Et₃N (0.18 mL, 1.26 mmol, 1 equiv), K₂CO₃ (0.35 g, 2.52 mmol, 2 equiv) and Boc₂O (0.285 g, 1.3 mmol, 1.03 equiv) were added. The mixture was stirred overnight while gradually warming to r.t. The precipitate was dissolved in H₂O (5 mL) and the mixture was diluted with additional CHCl₃ (5 mL). The layers were separated and the organic layer was washed with H₂O (3 × 10 mL), 1 M HCl (2 × 10 mL), 2 N NaOH (2 × 10 mL) and sat. NaCl (2 × 10 mL). After drying (MgSO₄), the organic fractions were filtered and solvents were removed in vacuo. The resulting residue was purified by flash chromatography (MeOH–CH₂Cl₂, 2.5%), to give **1d** (302 mg, 79%).

Following the general procedure for dehydration, compound **1d** (224 mg, 0.74 mmol) gave a 1:8.6 mixture (191 mg, 64%) of *tert*-butyl-benzyl(cyclohex-3-enyl)carbamate⁴ (**2d**) and *tert*-butyl benzyl(*cis*-4-iodocyclohexyl)carbamate (**3d**) after flash chromatography (EtOAc–hexane, 3 → 10%). Both compounds had the same *R_f* value. Reaction of 142 mg of the **2d**–**3d** mixture (0.32 mmol of **3d**, 0.35 mmol of **2d** + **3d**) with DBU (1 equiv), gave the olefin **2d** (100 mg, >99%) as a colourless oil.

2d–**3d** Mixture

Oil; *R_f* = 0.17 (EtOAc–hexane, 10%).

¹H NMR (400 MHz, CDCl₃): δ = 7.38–7.16 (m, 48 H, ArH), 5.57 (s, 2 H, CH=CH), 4.75 (s, 8.6 H, HCl), 4.43 (br s, 20.2 H, HCN in **2d**, NCH₂ in **2d**, NCH₂ in **3d**), 4.18 (br s, 8.6 H, HCN in **3d**), 2.16–1.24 [m, 161.2 H, 3 × CH₂ in **2d**, 4 × CH₂ in **3d**, C(CH₃)₃ in **2d**, C(CH₃)₃ in **3d**].

¹³C NMR (100 MHz, CDCl₃): δ = 155.9, 140.6 (C), 128.3, 126.7, 126.5, 125.6 (CH), 80.0, 79.8 (C), 54.0 (CH), 46.4, 35.9 (CH₂), 35.1 (CH), 29.8 (CH₂), 28.5 (CH₃), 27.1, 26.0 (CH₂).

tert-Butylcarbamates

Following the general procedure for dehydration, compound **1c** (1.08 g, 5 mmol) gave a 1:1.5 mixture (1.26 g, 92%) of *tert*-butylcyclohex-3-enylcarbamate (**2c**) and *tert*-butyl-*cis*-4-iodocyclohexylcarbamate (**3c**) after flash chromatography (EtOAc–hexane, 1% to separate excess Ph₃P and then EtOAc–hexane, 10% to obtain products). A part of this mixture (520 mg) was re-purified (EtOAc–hexane, 3 → 5%) to obtain olefin **2c** (138 mg, 37%) as a crystalline colorless solid and compound **3c** (338 mg, 55%). An additional fraction of the mixture (628 mg, 1.35 mmol of **3c**, 2.25 mmol of **2c** + **3c**) was further treated with DBU as described above, to give olefin **2c** (426 mg, 96%) as a colorless crystalline solid; mp 52–54 °C (Lit.³ mp 52–54 °C).

3c

Crystalline colorless solid; mp 98–100 °C.

IR (KBr): 3299, 2969, 2936, 1680, 1533, 1365, 1322, 1276, 1256, 1229, 1177, 1162, 1044, 1017 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 4.68 (br s, 1 H, HCl), 4.56 (br s, 1 H, NH), 3.54 (br s, 1 H, HCN), 2.14–1.99 (m, 2 H, 2 × CHHCHI), 1.89–1.55 (m, 6 H, 2 × CHHCHI, 2 × CH₂CHN), 1.43 [s, 9 H, C(CH₃)₃].

¹³C NMR (100 MHz, CDCl₃): δ = 155.3, 79.4 (C), 48.2 (CH), 35.5 (CH₂), 33.4 (CH), 30.2 (CH₂), 28.5 (CH₃).

MS (EI): *m/z* (%) = 325.0/326.0/327.0 [M]⁺.

Anal. Calcd for C₁₁H₂₀INO₂: C, 40.63; H, 6.20; N, 4.31. Found: C, 40.92; H, 6.35; N, 4.18.

N-Benzoylated Compounds

Following the general procedure for dehydration, compound **1e**^{12b} (1.10 g, 5 mmol) gave a 1.6:1 mixture (1.15 g, 92%) of *N*-(cyclohex-3-enyl)benzamide (**2e**) and *cis*-*N*-(4-iodocyclohexyl)benzamide (**3e**) after flash chromatography (EtOAc–hexane, 6 → 25%). Part of it (415 mg) was re-purified (EtOAc–hexane, 10%) to obtain **2e** (186 mg, 56%) and **3e** (191 mg, 35%). An additional fraction of the mixture (602 mg, 0.92 mmol of **3e**, 2.40 mmol of **2e** + **3e**) was further treated with DBU as described above, to obtain olefin **2e**.

2e

Yield: 479 mg (99%); crystalline colorless solid; mp 114–116 °C.

IR (KBr): 3322, 3017, 2940, 1632, 1579, 1544, 1492, 1329, 718, 693, 656 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 7.75 (d, *J* = 7.4 Hz, 2 H, ArH_o), 7.47 (t, *J* = 7.4 Hz, 1 H, ArH_p), 7.40 (t, *J* = 7.4 Hz, 2 H, ArH_m), 6.25 (br s, 1 H, NH), 5.76–5.69 (m, 1 H, CH=CH), 5.68–5.60 (m, 1 H, CH=CH), 4.37–4.26 (m, 1 H, HCN), 2.53–2.42 (m, 1 H, CH=CH-CH-N), 2.28–2.07 (m, 2 H), 2.06–1.89 (m, 2 H), 1.76–1.64 (m, 1 H).

¹³C NMR (100 MHz, CDCl₃): δ = 167.0, 135.0 (C), 131.4, 128.6, 127.2, 127.0, 124.5 (CH), 45.0 (CH), 31.8, 28.0, 23.5 (CH₂).

MS (EI): *m/z* (%) = 201.1/202.1/203.1 [M]⁺.

Anal. Calcd for C₁₃H₁₅NO: C, 77.58; H, 7.51; N, 6.96; O, 7.95. Found: C, 77.31; H, 7.46; N, 6.87.

3e

Crystalline colorless solid; mp 162–164 °C.

IR (KBr): 3435, 3285, 2949, 1630, 1535, 1492, 1342, 1328, 690 cm⁻¹.

¹H NMR (300 MHz, CDCl₃): δ = 7.83–7.74 (m, 2 H, ArH), 7.55–7.39 (m, 3 H, ArH), 6.16 (br s, 1 H, NH), 4.76 (s, 1 H, HCl), 4.20–4.00 (m, 1 H, HCN), 2.20–1.70 (m, 8 H).

¹³C NMR (75 MHz, CDCl₃): δ = 166.9, 134.8 (C), 131.6, 128.7, 127.0, 47.7 (CH), 35.5 (CH₂), 33.6 (CH), 29.8 (CH₂).

MS (EI): *m/z* (%) = 329.0/330.0/331.0 [M]⁺.

Anal. Calcd for C₁₃H₁₆INO: C, 47.43; H, 4.90; I, 38.55; N, 4.26. Found: C, 47.28; H, 4.79; N, 4.28.

N-Trifluoroacetylated Compounds

Following the general procedure for dehydration, compound **1f**²³ (135 mg, 0.64 mmol) gave rise to a 1:1.2 mixture (116.8 mg, 69%) of *N*-(cyclohex-3-enyl)-2,2,2-trifluoroacetamide³ (**2f**) and *cis*-*N*-(4-iodocyclohexyl)-2,2,2-trifluoroacetamide (**3f**) after flash chromatography (EtOAc–hexane, 2 → 6%). Part of it (65.4 mg) was re-purified (EtOAc–hexane, 2 → 3 → 4%) to obtain **2f** (15.5 mg, 31%) and **3f** (38.9 mg, 46%). An additional fraction of the mixture (30 mg, 0.062 mmol of **3f**, 0.114 mmol of **2f** + **3f**) was further treated with DBU as described above, to obtain olefin **2f** (21.8 mg, 99%); mp 59–61 °C (Lit.³ mp 59–60 °C).

3f

Crystalline colorless solid; mp 64–66 °C.

¹H NMR (300 MHz, CDCl₃): δ = 6.41 (br s, 1 H, NH), 4.73 (s, 1 H, HCl), 3.91 (m, 1 H, HCN), 2.28–1.60 (m, 8 H).

¹³C NMR (75 MHz, CDCl₃): δ = 156.6 (d, *J* = 37.2 Hz, C), 115.9 (d, *J* = 288.1 Hz, C), 48.3 (CH), 35.2 (CH₂), 32.1 (CH), 28.9 (CH₂).

HRMS-ESI: *m/z* [M + H]⁺ calcd for C₈H₁₂F₃INO: 321.9916; found: 321.9922.

N-Tosylated Compounds

Following the general procedure for dehydration, compound **1g**^{12a} (2.69 g, 10 mmol) gave a 1.3:1 mixture (2.81 g, 92%) of *N*-(cyclohex-3-ene)-*p*-toluenesulfonamide²⁴ (**2g**) and *N*-(*cis*-4-iodocyclohexyl)-*p*-toluenesulfonamide (**3g**) after flash chromatography (EtOAc–hexane, 10 → 25%). Both compounds showed the same *R_f* value. Reaction with DBU, starting from the **2g**–**3g** mixture (2.81 g, 3.98 mmol of **3g**, 9.15 mmol of **2g** + **3g**), gave olefin **2g** (2.18 g, 95%); mp 65–67 °C (Lit.²⁴ mp 65.8–67.0 °C).

2g–3g Mixture

Oil; *R_f* = 0.32 (EtOAc–hexane, 25%).

¹H NMR (400 MHz, CDCl₃): δ = 7.78 (d, *J* = 8.2 Hz, 4.6 H, 2 × HC–C–S in **2g**, 2 × HC–C–S in **3g**), 7.27 (d, *J* = 8.2 Hz, 4.6 H, 2 × HC–C–Me in **2g**, 2 × HC–C–Me in **3g**), 5.61–5.53 (m, 1.3 H, CH=CH), 5.43 (dtd, *J* = 5.7, 4.5, 2.2 Hz, 1.3 H, CH=CH), 5.37 (d, *J* = 6.9 Hz, 1 H, NH in **3g**), 5.27 (d, *J* = 7.8 Hz, 1.3 H, NH in **2g**), 4.48 (br s, 1 H, HCl), 3.45–3.33 (m, 1.3 H, HCN in **2g**), 3.21 (br s, 1 H, HCN in **3g**), 2.39 (s, 6.9 H, Me in **2g**, Me in **3g**), 2.20–2.09 (m, 1.3 H, N–CH–HHC–HC=CH), 2.07–1.92 (m, 4.6 H, HC=CH–CH₂–CH₂, 2 × CHH–CH–I), 1.84 (dq, *J* = 16.0, 5.4, 2.7 Hz, 1.3 H, N–CH–HHC–HC=CH), 1.76–1.67 (m, 1.3 H, HC=CH–CH₂–CHH), 1.67–1.56 (m, 6 H, 2 × CHH–CH–I, 2 × N–CH–CH₂ in **3g**), 1.55–1.43 (m, 1.3 H, HC=CH–CH₂–CHH).

¹³C NMR (75 MHz, CDCl₃): δ = 143.3, 143.2, 138.2, 138.1 (C), 129.7 (2 × CH), 126.9 (3 × CH), 124.0, 50.9, 49.0 (CH), 35.0, 32.3 (CH₂), 31.6 (CH), 30.8, 28.8, 23.6 (CH₂), 21.6 (2 × CH₃).

Supporting Information for this article is available online at <http://www.thieme-connect.com/ejournals/toc/synthesis>.

Acknowledgment

J.M.C. thanks MEC (Spain) for a grant (SAF2006-08764-C02-01), Comunidad de Madrid (S/SAL-0275-2006) and Instituto de Salud Carlos III [RED RENEVAS (RD06/0026/1002)]. M.A.-P. thanks Dr. Stephen M. Goldup and Dr. Bryan D. Koivisto for helpful proofreading of the manuscript.

References

- (1) New address: Facultad de Ciencias Químicas, Universidad Complutense de Madrid, Avda. Complutense s/n, 28040-Madrid, Spain.
- (2) (a) Gómez-Sánchez, E.; Soriano, E.; Marco-Contelles, J. *J. Org. Chem.* **2008**, *73*, 6784. (b) Gómez-Sánchez, E.; Soriano, E.; Marco-Contelles, J. *J. Org. Chem.* **2007**, *72*, 8656. (c) Gómez-Sánchez, E.; Marco-Contelles, J. *Lett. Org. Chem.* **2006**, *3*, 827.
- (3) Kapferer, P.; Vasella, A. *Helv. Chim. Acta* **2004**, *87*, 2764; and references therein.
- (4) Quirante, J.; Vila, X.; Escolano, C.; Bonjoch, J. *J. Org. Chem.* **2002**, *67*, 2323; and references therein.
- (5) For a review including recent syntheses of epibatidine, see: (a) Olivo, H.; Hemenway, M. S. *Org. Prep. Proc. Int.* **2002**, *34*, 1. For other reviews focused on biological properties, see: (b) Daly, J. W. *J. Med. Chem.* **2003**, *46*, 445. (c) Romaneli, M. N.; Gualteri, F. *Med. Res. Rev.* **2003**, *23*, 393. (d) Broka, C. A. *Med. Chem. Res.* **1994**, *4*, 449.
- (6) Triggle, D. J.; Kwon, Y. W.; Abraham, P.; Pitner, J. B.; Mascarella, S. W.; Carroll, F. *J. Med. Chem.* **1991**, *34*, 3164.
- (7) Kwak, Y.-S.; Winkler, J. D. *J. Am. Chem. Soc.* **2001**, *123*, 7429.
- (8) (a) Jehanno, E.; Vaultier, M. *Tetrahedron Lett.* **1995**, *36*, 4439. (b) Singleton, D. A.; Redman, A. M. *Tetrahedron Lett.* **1994**, *35*, 509. (c) Noiret, N.; Youssoufi, A.; Carboni, B.; Vaultier, M. *J. Chem. Soc., Chem. Commun.* **1992**, 1105.
- (9) (a) Corey, E. J.; Loh, T.-P.; AchyuthaRao, S.; Daley, D. C.; Sarshar, S. *J. Org. Chem.* **1993**, *58*, 5600. (b) Pfister, J. R.; Wymann, W. E. *Synthesis* **1983**, 38.
- (10) Maier, M. E.; Lapeva, T. *Synlett* **1998**, 891.
- (11) (a) Gómez-Sánchez, E.; Marco-Contelles, J. *J. Heterocycl. Chem.* **2006**, *43*, 1455. (b) Gómez-Sánchez, E.; Marco-Contelles, J. *Tetrahedron* **2005**, *61*, 1207.
- (12) In fact, compound **1a**·HCl has been previously used for the preparation of 7-azabicyclo[2.2.1]heptanes which did not require a cyclohexene-type precursor. Thus, under certain conditions and derivatizations, intramolecular cyclization is favored. See: (a) Trudell, M. L.; Cheng, J. *Org. Lett.* **2001**, *3*, 1371. (b) Olivo, H. F.; Hemenway, M. S. *J. Org. Chem.* **1999**, *64*, 8968. (c) Hassner, A.; Belostotskii, A. M. *Tetrahedron Lett.* **1995**, *36*, 1709. (d) In this paper we are presenting a straightforward and general strategy, which affords N-substituted cyclohex-3-enamines, in themselves interesting synthetic units, which could be used as precursors of certain 7-azabicyclo[2.2.1]heptanes and 7-azabicyclo[2.2.1]hept-2-enes through subsequent cyclization.
- (13) (a) Zhu, Z.; Espenson, J. H. *J. Org. Chem.* **1996**, *61*, 324; and references therein. (b) Laali, K.; Gerzina, R. J.; Flajnik, C. M.; Geric, C. M.; Dombroski, A. M. *Helv. Chim. Acta* **1987**, *70*, 607; and references therein.
- (14) Xu, F.; Simmons, B.; Reamer, R. A.; Corley, E.; Murry, J.; Tschaen, D. *J. Org. Chem.* **2008**, *73*, 312.
- (15) See experimental section.
- (16) Noguchi, H.; Aoyama, T.; Shioiri, T. *Heterocycles* **2002**, *58*, 471.
- (17) Marinko, P.; Obreza, A.; Peterlin-Mašič, L.; Krbavčič, A.; Kikelj, D. *J. Heterocycl. Chem.* **2000**, *37*, 405.
- (18) Lange, G. L.; Gottardo, C. *Synth. Commun.* **1990**, 1473.
- (19) A preliminary attempt to perform both steps in one pot gave rise to 20% of **2c** and 32% of **3c**, which is quite promising but requires further optimization.
- (20) Starting from 7 g of **1c**, 5.6 g of **2c** was obtained after purification.
- (21) The moderate yield obtained starting from compound **1f** might be due to its low solubility in CH₂Cl₂ and/or the ease of hydrolysis of the trifluoroacetamide group.
- (22) Boger, D. L.; Yohannes, D. *J. Org. Chem.* **1989**, *54*, 2498.
- (23) Plettenburg, O.; Hofmeister, A.; Kadereit, D.; Brendel, J.; Loehn, M. *PCT Int. Appl. WO2007012422*, **2007**; *Chem. Abstr.* **2007**, *146*, 206217.
- (24) Bayer, A.; Hansen, L. K.; Gautun, O. R. *Tetrahedron: Asymmetry* **2002**, *13*, 2407.